Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$5.79 - $8.6 $2.02 Million - $3 Million
-349,000 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$6.5 - $10.53 $225,608 - $365,485
-34,709 Reduced 9.05%
349,000 $2.83 Million
Q4 2020

Feb 02, 2021

SELL
$3.7 - $7.66 $18,544 - $38,391
-5,012 Reduced 1.29%
383,709 $2.48 Million
Q3 2020

Nov 05, 2020

BUY
$3.45 - $4.89 $10,657 - $15,105
3,089 Added 0.8%
388,721 $1.4 Million
Q2 2020

Aug 12, 2020

BUY
$3.32 - $5.34 $185,813 - $298,869
55,968 Added 16.98%
385,632 $1.77 Million
Q1 2020

May 12, 2020

BUY
$2.12 - $6.8 $30,740 - $98,600
14,500 Added 4.6%
329,664 $1.12 Million
Q4 2019

Jan 27, 2020

BUY
$2.25 - $5.8 $198,144 - $510,771
88,064 Added 38.78%
315,164 $1.61 Million
Q3 2019

Oct 31, 2019

BUY
$2.22 - $3.39 $79,698 - $121,701
35,900 Added 18.78%
227,100 $550,000
Q2 2019

Aug 15, 2019

SELL
$1.8 - $3.3 $283,860 - $520,410
-157,700 Reduced 45.2%
191,200 $415,000
Q1 2019

May 03, 2019

SELL
$2.41 - $5.91 $84,557 - $207,358
-35,086 Reduced 9.14%
348,900 $946,000
Q4 2018

Feb 08, 2019

BUY
$3.94 - $9.7 $785,852 - $1.93 Million
199,455 Added 108.09%
383,986 $1.84 Million
Q3 2018

Nov 13, 2018

BUY
$8.6 - $11.26 $328,769 - $430,458
38,229 Added 26.13%
184,531 $1.75 Million
Q2 2018

Aug 15, 2018

SELL
$9.52 - $12.15 $246,587 - $314,709
-25,902 Reduced 15.04%
146,302 $1.42 Million
Q1 2018

May 11, 2018

SELL
$6.7 - $12.95 $167,017 - $322,817
-24,928 Reduced 12.65%
172,204 $1.81 Million
Q4 2017

Feb 06, 2018

BUY
$5.07 - $7.92 $434,154 - $678,205
85,632 Added 76.8%
197,132 $1.26 Million
Q3 2017

Nov 15, 2017

BUY
$5.4 - $8.47 $602,100 - $944,405
111,500
111,500 $853,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.